Analyst Price Targets — OM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 12:28 pm | Marie Thibault | BTIG | $15.00 | $4.54 | TheFly | Outset Medical price target lowered to $15 from $17 at BTIG |
| January 7, 2026 12:35 pm | Rick Wise | Stifel Nicolaus | $8.00 | $4.29 | TheFly | Outset Medical price target lowered to $8 from $14 at Stifel |
| December 17, 2025 1:50 pm | Shagun Singh | RBC Capital | $7.00 | $4.02 | TheFly | Outset Medical price target lowered to $7 from $17 at RBC Capital |
| November 11, 2025 9:57 am | Rick Wise | Stifel Nicolaus | $14.00 | $12.07 | StreetInsider | Outset Medical Inc. (OM) PT Lowered to $14 at Stifel |
| July 14, 2025 11:31 am | Marie Thibault | BTIG | $37.00 | $19.92 | TheFly | Outset Medical price target lowered to $37 from $45 at BTIG |
| March 21, 2025 6:49 pm | Rick Wise | Stifel Nicolaus | $15.00 | $10.05 | TheFly | Outset Medical price target adjusted to $15 at Stifel after reverse stock split |
| August 8, 2024 3:56 am | Shagun Singh | RBC Capital | $3.00 | $3.40 | StreetInsider | RBC Capital Downgrades Outset Medical Inc. (OM) to Sector Perform |
| June 21, 2024 6:20 am | Shagun Singh | RBC Capital | $6.00 | $3.59 | TheFly | Outset Medical upgraded to Outperform at RBC on expected return to growth |
| April 17, 2024 10:55 am | Rick Wise | Stifel Nicolaus | $6.00 | $2.27 | StreetInsider | Stifel on Outset Medical Inc. (OM): 'we expect this home hemodialysis agreement will be a positive incremental sales driver in 2025 and beyond' |
| April 8, 2024 6:12 am | Maria Thibault | BTIG | $6.00 | $2.05 | StreetInsider | BTIG Starts Outset Medical Inc. (OM) at Buy |
Latest News for OM
ZUG, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Binance has announced that the Digital Asset under the Certificates will be subject to a MANTRA (OM) token swap, redenomination and rebranding to MANTRA (MANTRA): OM tokens will assume the ticker of MANTRA tokens on Binance; All OM tokens will be swapped to MANTRA at a ratio of 1 OM = 4 MANTRA though a non-dilutive split; Implementation is currently expected to…
Shares of Outset Medical, Inc. (NASDAQ: OM - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy
Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025.
Outset Medical (NASDAQ: OM - Get Free Report) and KORU Medical Systems (NASDAQ: KRMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings. Analyst Recommendations This is a breakdown
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OM.
U.S. House Trading
No House trades found for OM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.